Zoldonat inj. contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-hydroxy-2imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate.
Zoldonat is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density or prevalent vertebral fracture, Zoldonat reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Zoldonat reduces the incidence of new clinical fractures.